Navamedic launches new generic drug
Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced the launch of a new generic pharmaceutical product. The new generic can replace Viagra and is Navamedic's 15th product launch so far this year.
The product now being launched is Sildenafil Aspen, which is used by men suffering from erectile dysfunction. The generic drug can replace Pfizer's Viagra. The product will be introduced across all Navamedic's key markets in the Nordic, except Norway.
Navamedic has been developing its portfolio of generic drugs since 2011 and is aiming to become a significant provider of generic drugs in the Nordic and Benelux markets. The cooperation with Aspen of South Africa, one of the world's largest manufacturers of generic pharmaceuticals, is a cornerstone of this strategy. The cooperation is proving successful, providing Navamedic with an attractive pipeline of new products.
For further information, please call Håkan Josephsson, CEO, telephone +46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).